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 Abstract  We have been conducting research on regeneration of the damaged central 
nervous system, which includes (i) regrowth of the disrupted neuronal axons, (ii) 
replenishment of lost neural cells, and (iii) recovery of lost neural functions. In 
particular, we have investigated cell therapy for treating spinal cord injury. 
Considering the ethical issues related to fetal cells and embryonic stem cells, there 
is increasing interest in stem cell technology involving induced pluripotent stem 
(iPS) cells. Here, we wish to introduce our achievements in iPS cell-based therapy. 
In addition to their application for cell therapy, iPS cell technologies provide versa-
tile tools for investigation of the pathophysiology of various diseases. Indeed, dis-
ease model mice do not always recapitulate the pathophysiology of human diseases. 
However, iPS cell technology can provide some solutions because neural cells at 
various developmental stages and a wide variety of cells with the same genetic 
information as that of patients can be obtained for further investigation. Through 
these investigations, I have had numerous collaborations with life science indus-
tries, including pharmaceutical companies, and generated various patents. Some 
examples of these achievements will be discussed here. 
 1  The Challenge of Regeneration of the Central 
Nervous System 
 It had been long believed that the damaged central nervous system (CNS) does not 
regenerate upon injury  [ 1 ] . However, we have been challenging this dogma for 
many years by taking advantage of various biotechnologies, including stem cells 
 [ 2– 11 ] , in collaboration with academia and various pharmaceutical companies. 
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Before introducing the details of our past and on-going research, I wish to introduce 
the concepts of regeneration of the CNS, which include (i) regrowth of disrupted 
neuronal axons, (ii) replenishment of lost neural cells, and (iii) recovery of lost neu-
ral functions. Investigation of CNS regeneration is indeed an exciting and profound 
research  fi eld, but also provides enormous opportunities for industry-university coop-
eration. In fact, through investigations of CNS regeneration and stem cell biology, 
I have obtained 30 patents and  fi led 57 patents pending.
  (i)  Regrowth of disrupted neuronal axons 
 Axonal regeneration hardly takes place in the damaged CNS because of the 
presence of large amounts of inhibitors  [ 9,  10 ] , including myelin-derived pro-
teins (e.g. MAG, Nogo-A, and OMgp)  [ 12– 17 ] , and glial scar-derived factors 
(e.g. CSPG)  [ 18,  19 ] , and extracellular matrix-derived factors (e.g. sema-
phorins). In a previous collaboration with Dainippon Sumitomo Pharma Co. 
Ltd., we demonstrated the therapeutic effects of a speci fi c inhibitory com-
pound (SM-216289) against semaphorin3A (Sema3A)  [ 20 ] , a major inhibitor 
of axonal regeneration  [ 21– 23 ] , in spinal cord injury (SCI) using a rat com-
plete transection model. Remarkably, we found that this Sema3A inhibitor 
induced signi fi cant functional recovery as well as enhanced axonal regenera-
tion at the lesion site and robust Schwann cell-mediated myelination. This 
evidence suggests the possibility of using Sema3A inhibitors for the treat-
ment of human SCI patients in the future, which is being continuously inves-
tigated through the collaboration between our group at Keio University and 
Dainippon Sumitomo Pharma Co. Ltd. In addition to treatment of SCI, we 
found another application of the Sema3A inhibitor in the ophthalmological 
 fi eld. In collaboration with the Department of Ophthalmology at Keio 
University School of Medicine and Dainippon Sumitomo Pharma Co. Ltd., 
we showed that the Sema3A inhibitor was able to treat peripheral nerve dam-
age of the cornea. Treatment with the Sema3A inhibitor promoted a robust 
network of regenerating nerves as well as functional recovery of corneal sen-
sation through subconjunctival injections in a mouse keratoplasty model  [ 24 ] , 
suggesting a novel therapeutic strategy for treating peripheral nerve damage 
of the cornea. 
  (ii)  Replen fi shment of lost neural cells 
 It is obvious that  replenishment of lost neural cells will be a very important 
aim of stem cell technology. In our previous studies  [ 25– 30 ] , we found that 
transplanted neural stem cells (NSCs) survived and differentiated into neurons, 
astrocytes, and oligodendrocytes, which are three major cellular components 
of the CNS. Graft-derived neurons formed synapses with host neurons and 
integrated with host neuronal circuits. Graft-derived oligodendrocytes were 
shown to participate in re-myelination of host axons in SCI models  [ 28,  30 ] , 
which signi fi cantly contributes to functional recovery after SCI  [ 30 ] . It is pos-
sible that graft-derived astrocytes and undifferentiated NSCs produce various 
trophic factors that support angiogenesis  [ 27– 29 ] , cellular survival, and axonal 
regeneration of host axons including 5-HT-positive raphe-spinal tracts involved 
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in the locomotive functions of hindlimbs  [ 27– 29 ] . Thus, these  fi ndings suggest 
that both cellular replacement mechanisms and trophic mechanisms are 
responsible for the effects of stem cell therapy in SCI models. The details of 
stem cell therapy for treating SCI will be described in the later sections. 
  (iii)  Recovery of lost neural functions 
 Considering the therapeutic applications of stem cells, it is obvious that 
recovery of lost neural functions is an important aspect of regeneration of the 
damaged CNS. For functional recovery, we are interested in rehabilitation 
and its combination with blockade of the inhibitors of axonal regeneration 
 [ 31 ] , and/or stem cell transplantation. 
 2  NSCs and Stem Cell Therapy for Treating SCI 
 NSCs are somatic stem cells in the CNS, which are characterized by their multipo-
tency and self-renewal. A single NSC is capable of generating various kinds of cells 
within the CNS, including neurons, astrocytes, and oligodendrocytes. Because of 
these characteristics, there has been a strong research focus on NSCs and neural 
progenitor cells for both basic developmental biology and therapeutic applications 
for treating the damaged CNS  [ 2 ] . 
 2.1  Basic Biology and Tools for Investigation of NSCs 
 It is understood that (i) speci fi c immunocytochemical markers, (ii) selective culture 
methods, and (iii) technologies for the prospective identi fi cation and isolation of 
NSCs and early precursor cells (neural stem/precursor cells, NS/PCs) have greatly 
contributed to the rapid progress of the investigation of NSCs  [ 8 ] .
  (i)  Speci fi c immunocytochemical markers 
 Speci fi c marker molecules for NSCs include Musashi1 (an RNA-binding pro-
tein)  [ 32– 38 ] , nestin  [ 39,  40 ] , and some Sox family transcription factors  [ 41 ] . 
  (ii)  Selective culture methods 
 The neurosphere method involves suspension culture with  fi broblast growth 
factor-2 (FGF-2) and/or epidermal growth factor in a de fi ned medium  [ 42 ] , 
which has been widely used as a versatile method for selective expansion of 
NSCs. Neurosphere culture allowed us to expand NSCs in an undifferenti-
ated state. NS/PCs obtained by neurosphere culture have been used for trans-
plantation into patients with SCI and Parkinson’s disease. We applied 
neurosphere culture for ef fi cient induction of NSCs from pluripotent stem 
cells including embryonic stem (ES) cells and induced pluripotent stem (iPS) 
cells  [ 43– 45 ] . Brie fl y, we generated embryoid bodies (EBs) from mouse ES/
iPS cells in the presence of neural inducers (noggin or retinoic acid), resulting 
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in neurally biased differentiation of ES cells and a substantial number of 
NSCs. The NSCs within EBs were then expanded in the presence of FGF-2 
to give rise to primary neurospheres that were subsequently passaged to 
form secondary neurospheres. Interestingly, when we induced the differen-
tiation of primary neurospheres, they exclusively gave rise to neurons, but 
not glial cells. The majority of neurons derived from primary neurospheres 
were early projection neurons including forebrain type cholinergic neurons, 
mesencephalic dopaminergic neurons and spinal motor neurons. However, 
when we induced the differentiation of secondary neurospheres, they gave 
rise to neurons, astrocytes, and oligodendrocytes. Neurons derived from 
secondary neurons, including GABAergic interneurons as the major popula-
tion, were different from those derived from primary neurospheres. 
Furthermore, tertiary neurospheres gave rise to a higher proportion of glial 
cells. Therefore, this in vitro differentiation system of mouse pluripotent 
stem cells probably recapitulates the change of differentiation potential of 
NSCs, which occurs in vivo  [ 46 ] . Using these methods for neural differen-
tiation of pluripotent stem cells, we generated patents, including “Process 
for Producing Nerve Stem Cells, Motor Neurons, and GABAergic Neurons 
from Embryonic Stem Cells,” and “Remedy for Dysmnesia,” and licensed 
out these patents and related technologies to various pharmaceutical compa-
nies and bio-ventures. 
 (iii)  Technologies for the prospective identi fi cation and isolation of NSCs and 
early precursor cells 
 For the prospective identi fi cation of NSCs, combinations of antibodies against 
cell surface antigens  [ 47,  48 ] and NSC-speci fi c  fl uorescence reporters  [ 49–
 56 ] have been used  [ 8 ] . For the latter strategy, we constructed a reporter gene 
consisting of cDNA encoding a  fl uorescent protein (green  fl uorescent pro-
tein, Venus, Kusabira Orange, or ffLuc-cp156  [ 57 ] ), which was placed under 
the control of the 2nd intronic enhancer of the  nestin gene or enhancer ele-
ments of the  Musashi1 gene for speci fi c expression in NSCs. By taking 
advantage of these strategies using cell type-speci fi c promoter/enhancer ele-
ments and  fl uorescent reporter genes, we generated several patents for the 
prospective identi fi cation and isolation of NSCs (“Enriched Preparation of 
Human Fetal Multipotential Neural Stem Cells”) and dopaminergic neurons 
(“Method of Concentrating and Separating DOPAMINergic Neurons”)  [ 58 ] . 
 In addition to (i)–(iii), there are rapidly accumulating studies of the signal-
ing mechanisms involved in the self-renewal and differentiation of NSCs. In 
the related  fi eld, we have published numerous scienti fi c reports and generated 
various patents including “Numb Protein Expression Inhibitor Making Use 
Musashi,” “Method of Detecting Activation of Notch Signal Transmission 
System,” “Signal Transduction System Activator,” “Agent for Inhibiting 
Proliferation of Neural Stem Cells,” and “Method of Promoting Subsistence 
and/or Proliferation of Neural Stem Cells and Promoting Extension of 
Neurite, Promoter therefore, Pharmaceutical Composition Containing Neural 
Stem Cells, Method of Assay and Method of Screening.” 
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 2.2  Stem Cell Therapy for Treating SCI 
 2.2.1  Pathophysiology of SCI 
 The pathophysiology of SCI is known to change over time after the initial injury. SCI 
is initiated by primary mechanical trauma (the so called “primary injury”) and fol-
lowed by a series of secondary events (the so called “secondary injury”)  [ 8 ] . The sec-
ondary injury includes hemorrhage, ischemia, and hypoxia (which take place within 
seconds), production of pro-in fl ammatory cytokines and glutamate cytotoxicity 
(which take place within minutes), and production of free radicals and nitric oxide, 
protease activation, and neutrophil invasion (which take place within hours). These 
events characterize the strong in fl ammation at the acute phase of SCI. The acute 
phase of SCI lasts for several days after the primary mechanical trauma, which is 
followed by delayed events (the so called “subacute phase”) including neural apop-
tosis, astrogliosis, and axonal demyelination. The subacute phase is followed by an 
irreversible stage (the so called “chronic phase”) including severe axonal degenera-
tion, cyst formation, and permanent loss of spinal functions. The chronic phase is 
considered to begin at 6 weeks in rodents and 6 months in humans after the primary 
mechanical trauma. This phenomenon is not observed in salamanders in which the 
spinal cord regrows even after tail amputation  [ 59 ] . The damaged spinal cord hardly 
regenerates in adult mammalian animals because of limited activation of endoge-
nous stem cells and axonal regeneration, which is why there is a need for blockade 
of the inhibitors of axonal regeneration, and transplantation of NSCs for treating the 
SCIs of humans. 
 2.2.2  Interventions at the Acute Phase 
 In the acute phase of SCI, in fl ammatory cells such as neutrophils, hematogenous 
macrophages (blood-borne macrophages), and resident microglia accumulate at the 
lesion site. Because pro-in fl ammatory cytokines such as tumor necrosis factor  a , 
interleukin (IL)-1 b , and IL-6 are major regulators of in fl ammation, these cytokines 
are likely targets for potential pharmaceutical interventions for treating SCI  [ 60 ] . 
Among them, IL-6 induces the activation and invasion of microglia/macrophages 
within SCIs. Thus, in collaboration with Chugai Pharmaceutical Co. Ltd, we admin-
istered an anti-mouse IL-6 receptor antibody, MR16-1, to a mouse SCI model, 
resulting in improved functional recovery with reduced in fl ammation and astroglio-
sis, and enhanced tissue sparing  [ 61 ] . Furthermore, we have investigated the mecha-
nism of action of the anti-MR16-1 in more detail by focusing on the effect of 
temporary inhibition of IL-6 signaling in macrophages and microglia after SCI  [ 60 ] . 
We found that MR16-1 treatment reduced the in fi ltration of macrophages, but 
increased the number of microglia at the SCI. Thus, temporary inhibition of IL-6 
signaling must have induced switching of the major in fl ammatory cell type at the 
lesion from hematogenous macrophages to resident microglia, resulting in improved 
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tissue sparing and debris clearance for promotion of neural repair after SCI. Notably, 
a humanized antibody against the human IL-6 receptor (Actemra; tocilizumab) is 
already used clinically, and our  fi ndings suggest its potential application for the 
treatment of SCI patients at the acute phase. Keio University and Chugai 
Pharmaceutical Co. Ltd have  fi led patents covering the therapeutic actions of block-
ing antibodies against IL-6 signaling during the acute phase of SCI (“Therapeutic 
Agent for Spinal Cord Injury Comprising Interleukin-6”) in various countries. 
 2.2.3  Stem Cell Transplantation at the Sub-acute Phase 
 Considering the time course of secondary injury, the most appropriate time point for 
transplantation of NSCs is important. In rodent SCI models, we performed trans-
plantation of NS/PCs at 9 days after injury, i.e., after the acute in fl ammatory phase 
and before the astroglial scar becomes prominent  [ 8 ] . In mice, we found that trans-
plantation of NS/PCs at the chronic phase did not result in functional recovery  [ 62 ] . 
Thus, the chronic phase of SCI is not appropriate for therapeutic transplantation. 
The formation of large cysts and the development of glial scarring during the chronic 
phase might inhibit axonal regeneration (Nishimura et al. Submitted). In the case of 
humans and considering the time course of in fl ammation, it is assumed that NS/PCs 
should be transplanted by 4 weeks after the primary mechanical trauma. In relation 
to stem cell therapy of SCIs, we generated a patent entitled “Central Nervous System 
Neural Progenitor Cell which Induces Synapse-Forming Neurons in the Spinal 
Cord.” 
 2.2.4  Non-human Primate Models of SCI 
 While most studies of SCI have used rodent models, it is not easy to directly cor-
relate the results obtained in rodent models to clinical cases because of the func-
tional and anatomic differences of the spinal cord between rodents and primates. 
Previously, we developed a non-human primate model of contusive SCI at the C5 
level in the common marmoset. This model consisted of mild, moderate and severe 
contusive SCIs that were induced by dropping one of three different weights (15, 
17, or 20 g) onto the C5 level from a height of 50 mm. We also developed behavioral 
assays to monitor the motor functions of these common marmoset models of SCI by 
measurements of spontaneous motor activity, as well as bar grip and cage climbing 
tests  [ 63 ] . Using this model, we veri fi ed the therapeutic effects of transplantation of 
human fetal NSCs  [ 64 ] and infusion of hepatocyte growth factor (HGF)  [ 65 ] . 
By con fi rming the safety and utility in this non-human primate model, we initiated 
a Phase 1 clinical trial of HGF infusion for treatment of patients with amyotrophic 
lateral sclerosis in collaboration with Professor Masashi Aoki at Tohoku University 
and Kringle Pharma Co Ltd.  [ 66 ] . We also  fi led a patent for the common marmoset 
model of SCI in both Japan and the USA (“Method of Constructing Spinal Injury 
Model Monkey and Utilization Thereof”). 
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 2.2.5  Sources of Stem Cells for Treating SCI 
 We have demonstrated that transplantation of human fetal NSCs into a common 
marmoset model of SCI results in signi fi cant functional recovery. However, because 
of the ethical controversies, we are not allowed to perform clinical trials using fetal 
cells. Human ES cells are also somewhat controversial. Therefore, we became 
interested in iPS cell-derived NS/PCs, directly induced NSCs  [ 67 ] , and neural crest 
stem cells  [ 68 ] for transplantation into patients. These cells can be derived from 
adult tissues, including a patient’s own tissue, and are therefore not ethically 
controversial. 
 2.3  iPS Cell-Based Therapy for Treating SCI 
 2.3.1  Brief Summary of iPS Cell Technology 
 iPS cell technology was developed by Professor Shinya Yamanaka, the 2012 Nobel 
laureate for Physiology or Medicine, and colleagues at Kyoto University. In 2006, 
they published a study showing that somatic cells, such as adult skin  fi broblasts, can 
be reprogrammed into ES cell-like pluripotent stem cells by retroviral transduction 
of four genes encoding transcription factors, i.e.,  Oct4 ,  Sox2 ,  Klf4 , and  c-Myc  [ 69 ] . 
Since 2006, we have had a close collaboration with the Yamanaka Laboratory, aim-
ing for iPS cell-based therapy for treating SCI patients. In 2007, establishment of 
human iPS cells using retroviral or lentiviral transduction of reprogramming factors 
was reported by Yamanaka  [ 70 ] and Thomson  [ 71 ] . Subsequently, various methods 
have been published (reviewed by Okano  [ 72 ] for generating integration-free iPS 
cells, including episomal vectors, the Sendai viral vector, and modi fi ed RNA). 
 2.3.2  Transplantation of NSCs Derived from iPS Cells 
 First, we examined transplantation of NSCs derived from mouse iPS cells into a 
mouse SCI model. However, the investigation was not as straightforward as we had 
expected. We had already established mouse ES cells  [ 43,  44 ] , and induced various 
mouse iPS cell lines into secondary neurospheres. The resultant mouse iPS cell-derived 
secondary neurospheres gave rise to neurons, astrocytes, and oligodendrocytes, 
which was irrespective of their somatic origin or method of iPS cell production  [ 45 ] , 
in a similar manner as that of mouse ES cell-derived secondary neurospheres. 
However, when we transplanted these mouse iPS cell-derived secondary neuro-
spheres into mouse brains, varying tumorigenic propensities were observed depend-
ing on the somatic origin of the iPS cells  [ 45 ] . These observations indicated that 
epigenetic memory and completeness of reprogramming were involved in the tum-
origenic propensities of iPS cell-derived NSCs. Subsequently, we transplanted 
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non-tumorigenic iPS cell-derived NSCs (primary or secondary neurospheres) into 
mouse thoracic contusion injury models (Th10) to examine their therapeutic 
effects. 
 Interestingly, we found that transplantation of secondary neurospheres, but not 
primary neurospheres, resulted in signi fi cant and long-lasting functional recovery, 
indicating the importance of glial cells. We found that transplanted iPS cell-derived 
secondary neurospheres gave rise to neurons, astrocytes, and oligodendrocytes, and 
re-myelination was induced by graft-derived oligodendrocytes. Conversely, trans-
plantation of tumorigenic iPS cell-derived secondary neurospheres into SCI model 
mice resulted in functional recovery, but the effects were transient. Eventually, 
transplanted animals suffered from strong paralysis due to the effects of tumors. 
Thus, the safety issue concerning tumorigenicity is crucial for iPS cell-based ther-
apy of SCI. 
 Human iPS cells can be induced to differentiate into NSCs in a similar manner 
as that of mouse iPS cells, although additional passage(s) are required to obtain both 
neurons and glia from iPS cell-derived neurospheres. Thus, in the case of humans, 
we used tertiary neurosphere instead of secondary neurospheres for the following 
transplantation experiments. We screened human iPS cell lines and found that NSCs 
derived from the 201B7 human iPS cell line were non-tumorigenic (Okada et al., 
submitted). We transplanted 201B7 human iPS cell-derived NSCs into mouse  [ 29 ] 
and common marmoset SCI models (Kobayashi et al., submitted), and found that 
grafted cells gave rise neurons, astrocytes, and oligodendrocytes and induced func-
tional recovery without any signs of tumorigenesis. 
 2.3.3  Future Direction of Cell Therapy for Treating SCI 
Using Reprogramming Technologies 
 Thus far, we have transplanted NSCs derived from mouse and human iPS cells into 
mouse and non-human primate SCI models, which results in functional recovery. 
Furthermore, using appropriate cell lines, there were no signs of tumorigenesis in 
transplanted animals during the time course of the observation. For clinical appli-
cation in the future, there are some concerns that need to be addressed. Considering 
that the critical time window for transplantation is within 4 weeks after SCI (pri-
mary mechanical trauma) and establishment of human iPS cells and subsequent 
induction of NSCs, which produce both neurons and glia, requires ~180 days, it is 
essential to prepare clinical grade banks (or stocks) of iPS cells and iPS cell-derived 
NSCs in advance. Clinical grade cell banks would allow these cells to be 
transplanted into any patient within the critical period. In addition, before iPS cell-
based therapy can be used in the clinic, we believe that the safety issues should be 
addressed as follows: (1) usage of integration-free iPS cells, (2) selection of an 
appropriate neural differentiation method, (3) selection of appropriate iPS cell 
clones by somatic origin, reprogramming, epigenetic  characterization, and  fl ow 
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cytometric analysis, (4) pre-evaluation of tumorigenesis in vivo, and (5) elimination 
of graft-derived tumors  [ 72 ] . 
 3  Disease Models 
 There is increasing interest in iPS cell-based modeling of diseases  [ 73 ] . In fact, 
disease model mice do not always recapitulate the pathophysiology of human dis-
eases. Furthermore, it is extremely dif fi cult to investigate what is taking place 
in vivo during the onset of disease, particularly neurological and psychiatric dis-
eases, partly because there is poor accessibility to pathological foci in the brain. 
These aspects complicate the investigation of human neurology. However, iPS cell 
technology can provide some solutions because neural cells at various developmen-
tal stages and a wide variety of cells with the same genetic information as that of 
patients can be obtained for further investigation. In my laboratories, we have been 
characterizing various neurological and psychiatric diseases that are classi fi ed into 
the following categories: (1) diseases caused by disrupted gene regulation, (2) dis-
eases caused by structural abnormalities of the nervous system, (3) diseases caused 
by abnormal neural functions, (4) diseases caused by abnormal metabolism in the 
nervous system, and (5) late-onset neurological diseases including Alzheimer’s dis-
ease  [ 74 ] and Parkinson’s disease  [ 75 ] . Characterization of iPS cells derived from 
pediatric neurological disorders may recapitulate disease processes, at least par-
tially, which may contribute to drug development and future therapies. 
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